Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CYTX

Cytori Therapeutics (CYTX) Stock Price, News & Analysis

Cytori Therapeutics logo

About Cytori Therapeutics Stock (NASDAQ:CYTX)

Key Stats

Today's Range
$0.60
$0.64
50-Day Range
$0.20
$0.21
52-Week Range
$0.20
$0.75
Volume
5.03 million shs
Average Volume
915,302 shs
Market Capitalization
$13.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive CYTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytori Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CYTX Stock News Headlines

Cytori Cell Research Institute Inc.
Checkpoint Therapeutics Inc (CKPT)
7 market signals flashing red right now
Right now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all flashing red at the same time.tc pixel
Sage Therapeutics Inc SAGE
5 Biotech Stocks Under $10 Blasting Higher
8 Stocks Under $10 Ripping Higher
See More Headlines

CYTX Stock Analysis - Frequently Asked Questions

Cytori Therapeutics Inc (NASDAQ:CYTX) announced its quarterly earnings results on Tuesday, May, 14th. The biotechnology company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.20) by $0.02. The biotechnology company earned $0.70 million during the quarter. Cytori Therapeutics had a negative net margin of 242.60% and a negative trailing twelve-month return on equity of 272.70%.

Shares of Cytori Therapeutics reverse split on the morning of Thursday, May 24th 2018.The 1-10 reverse split was announced on Wednesday, May 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cytori Therapeutics investors own include Regulus Therapeutics (RGLS), Inovio Pharmaceuticals (INO), Shire (SHPG), Bank of America (BAC), BCE (BCE), Celldex Therapeutics (CLDX) and Micron Technology (MU).

Company Calendar

Last Earnings
5/14/2019
Today
10/20/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & Medical Instruments
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CYTX
CIK
1095981
Fax
N/A
Employees
37
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12.63 million
Net Margins
-242.60%
Pretax Margin
N/A
Return on Equity
-272.70%
Return on Assets
-56.23%

Debt

Debt-to-Equity Ratio
0.39
Current Ratio
0.46
Quick Ratio
0.30

Sales & Book Value

Annual Sales
$3.67 million
Price / Sales
3.74
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.35 per share
Price / Book
1.77

Miscellaneous

Outstanding Shares
22,160,000
Free Float
N/A
Market Cap
$13.74 million
Optionable
Not Optionable
Beta
1.96
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:CYTX) was last updated on 10/20/2025 by MarketBeat.com Staff
From Our Partners